High sensitivity (93.55%) and specificity (73.91%) of the test to discriminate between CCA from healthy individuals suggest that HSP70 autoantibodies might serve as a novel marker for CCA in addition to commonly used markers such as CA 19-9 (sensitivity 66% and specificity of 97%) [43] and CEA (sensitivity 68.0% and specificity of 81.5%) [44] which may, however, manifest similar performances for cancers other than CCA [13], [45], [46]. This evidence concerns the gene CEACAM5 and cholangiocarcinoma.